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Although surgical treatment is the centerpiece of our
specialty, what differentiates surgical oncology from
other areas in surgery is the oncology experience and
expertise needed in dealing with all aspects of cancer
management in a multidisciplinary fashion. … The
salient feature of differentiation is that surgical
oncology is both a technical and cognitive specialty
involving a chronic disease process.
What is a surgical oncologist? Ann Surg Oncol 1993;
1:4
Despite our stated purpose of surgical oncology as
a specialty, it would probably not surprise the readers
of the Annals that there is still a fairly widespread
perception among medical oncologists and members
of the pharmaceutical companies that ‘‘surgeons
spend their time in the operating room and have a
relatively minor role in prescribing oncology and
supportive drugs.’’ Recently, I talked with a senior
marketing executive of a major pharmaceutical
company who stated that their company would not
advertise in our journal, exhibit at our meeting, or
fund SSO educational grants or sponsorships. This
was because of their perception that sur-
geons—including surgical oncologists—neither pre-
scribe their drug products nor inﬂuence their use in
surgical patients. Perhaps less well understood by
both the medical oncology community and the
pharmaceutical leadership is that many, if not the
majority, of cancer patients look to the surgeon who
made the diagnosis and initiated the primary treat-
ment for advice about systemic therapy. Further-
more, surgical oncologists have led the way in
deﬁning predictors of survival outcomes for the
majority of cancers, thereby identifying those at
greatest risk of occult distant metastases, and hence
are knowledgeable as to which of their surgical pa-
tients might beneﬁt from systemic therapy.
While we may know this perception is untrue at an
individual level, there is nothing better than having
good data to break such molds of misperception.
That is why I was pleased with the enormous re-
sponse from our SSO members to a survey conducted
by the Annals of Surgical Oncology Editors and
Springer Verlag Publishers. One component of this
survey was to tabulate prescribing practice patterns
of 532 surgical oncologists. This is more than one-
third of the active membership and makes the survey
results very creditable and representative. (The entire
TABLE 1. On average, how many drug orders (inpatient or
outpatient) do you or a trainee under your supervision pre-
scribe each week? (520 responses)
Response percent Response count





More than 25 35.8% 186
None 4.8% 25
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survey results will be sent to SSO members in a sep-
arate mailing and can be viewed online at its website
http://www.surgonc.org/.)
Of the 532 surgeons who responded, almost 71%
listed their workplace as a university/teaching hos-
pital, and 16% are in private practice (the remainder
are in other categories). Their surgical oncology
specialty interests were gastrointestinal (55%), breast
(54%), melanoma (31%), hepatic/pancreatic (28%),
endocrine (12%), and sarcomas (12%) (up to three
areas could be identiﬁed). They were busy clinicians,
as illustrated by the fact that, on average each week,
45% of respondents saw 26–50 patients, 18% saw 51–
75 patients, and 8% saw more than 75 patients. More
than 83% referred their surgical patients to a pre-
scribing medical oncologist ‘‘often’’ or ‘‘very often.’’
Surgical oncologists do indeed prescribe drugs
frequently … perhaps at a rate that would surprise
some who are outside our ﬁeld. When asked: ‘‘on
average, how many drug orders do you or a trainee
under your supervision prescribe each week,’’ more
than one-third prescribed 25 or more drugs and an
additional one-third prescribed 11–25 drugs (see Ta-
ble 1). The breakdown of therapeutic drug categories
conﬁrms what would be expected for a high fre-
quency of prescribing drugs as a component of peri-
operative management (analgesics, antibiotics,
antiemetics). In addition, two-thirds of surgical on-
cologists each week either prescribed, recommended,
or administered oncology-related hormone agents. In
addition, 30% did so for chemotherapeutic agents
and growth factors and 21% did so for monoclonal
antibodies (Table 2). Finally, when asked ‘‘Over the
last twelve months, have you ordered or prescribed a
recently approved therapy or a therapy under inves-
tigation?’’ 51% responded afﬁrmatively.
The results of this survey, the largest on this subject
ever published, clearly demonstrate that our mem-
bership embraces a dual role of being surgeon and
oncologist. The management of the surgical patient
with cancer involves the blending of physician skills
and experience that uses both their technical skills in
the operating room and their cognitive skills in using
drugs and other systemic agents to get patients safely
through the perioperative period. These cognitive
skills are also used to manage patients cancer with
systemic agents as a member of the multidisciplinary
team.
The survey has some implications for the SSOand its
membership. First, it should continue to promote the
highest-quality multidisciplinary patient care and re-
search through educational activities at its Annual
Meeting and publications in the Annals of Surgical
Oncology. Second, it should continue to emphasize and
teach the indications, risks, and beneﬁts of using var-
ious drugs and systemic agents in surgical training
programs. Third, it should continue to incorporate the
testing and validation of cancer drugs and periopera-
tive drugs through clinical trials. Fourth, it should
continue to actively solicit grants and sponsorships
from the pharmaceutical and biotechnology sector to
help support the SSOs educational, research, and
trainingmissions.With all these ongoing activities, the
SSO and its membership will continue to bring high-
quality and comprehensive cancer care to our surgical
patients as both surgeon and oncologist.
TABLE 2. On average, how many times each week do you prescribe, recommend, or administer products in the following
therapeutic categories?
1–5 6–10 11–20 >20 Never Response count
Analgesics 14.7% 32.2% 25.5% 24.2% 3.4% 475
Antibiotics, antivirals, antifungals 35.3% 32.3% 16.5% 11.8% 4.3% 468
Antiemetics 35.6% 26.6% 14.8% 11.7% 11.2% 418
Anticoagulation 51.1% 18.2% 8.0% 4.5% 18.2% 401
Anti-inﬂammatory agents (including steroids) 49.9% 23.1% 9.9% 5.5% 11.7% 403
Cardiovascular agents 41.3% 16.1% 6.3% 1.6% 34.7% 380
Diuretics 48.1% 18.1% 2.1% 2.3% 29.5% 387
Gastrointestinal agents 36.7% 25.4% 9.8% 4.8% 23.4% 398
Hormone agents 43.5% 14.1% 6.0% 2.8% 33.7% 398
Chemotherapeutic agents 20.9% 4.8% 3.2% 1.3% 69.8% 374
Growth factors (bone marrow) 24.9% 3.0% 0.3% 0.3% 71.6% 366
Heparin products/antithrombosis 35.9% 22.1% 12.3% 10.0% 19.7% 390
Monoclonal antibodies 16.0% 5.2% 0.0% 0.0% 78.8% 368
Neuropsychiatric agents 39.1% 5.5% 1.1% 0.3% 54.1% 366
Respiratory agents 44.0% 11.4% 4.7% 1.9% 38.0% 361
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